We need these virus vaccine.
我们需要接种这些病毒疫苗。
Vaccines are the most effective against viruses.
疫苗对于病毒的防御是最有效果的。
Another set of systems can effectively support production not only in traditional areas such as antibodies, vaccines, recombinant proteins and blood products but also for emerging therapeutics like plasmids, viral vectors and nucleic acids.
另一套系统不仅可以有效支持抗体、疫苗、重组蛋白和血液制品等传统领域的生产，还可以有效支持质粒、病毒载体和核酸等新兴疗法的生产。
As one of the world's leading mRNA vaccine developers, Moderna focuses on cancer immunotherapy, including mRNA-based medicine R&D and virus prevention technologies.
作为全球领先的mRNA疫苗开发商之一，莫德纳专注于癌症免疫疗法，包括基于mRNA的药物研发和病毒预防技术。
In the vaccine field, GSK will continue to showcase its blockbuster products, including a shingles vaccine, which showed 100 percent protective efficacy in Chinese adults aged 50 and above as shown in the latest research data, and a bivalent HPV vaccine, the only HPV vaccine using the AS04 innovative adjuvant system.
在疫苗领域，葛兰素史克将继续展示其重磅产品，包括带状疱疹疫苗，如最新研究数据所示，该疫苗对50岁及以上的中国成年人显示出100%的保护效力，以及二价HPV疫苗，该疫苗是唯一使用AS04创新佐剂系统的HPV疫苗。
Peggy Fung, vice-president and head of GSK China Vaccines, said the spillover effect of CIIE is quite obvious as it is of great help to accelerate the introduction, approval, and market launch of innovative products.
葛兰素史克中国疫苗副总裁兼主管冯表示，CIIE的溢出效应非常明显，因为它对加快创新产品的引入、审批和上市有很大帮助。
For example, she said, the company's shingles vaccine was approved in China in May 2019 and was a key exhibit of the company during CIIE that year.
例如，她说，该公司的带状疱疹疫苗于2019年5月在中国获得批准，是该公司在当年CIIE期间的一个关键展品。
"Taking advantage of CIIE's spillover effect, we quickly completed commercial landing for the vaccine.
“利用CIIE的溢出效应，我们很快完成了疫苗的商业落地。
GSK has 23 other vaccine candidates in the development stage, including a respiratory syncytial virus (RSV) vaccine, which was approved by the United States Food and Drug Administration in May for the prevention of RSV infection in people aged 60 or older.
葛兰素史克还有23种其他候选疫苗处于开发阶段，其中包括一种呼吸道合胞病毒（RSV）疫苗，该疫苗于5月被美国食品和药物管理局批准用于预防60岁或以上人群感染RSV。
"We hope to bring this innovative vaccine to the Chinese market in the near future, which will be significant for the prevention and control of diseases in an aging society," she said.
她说：“我们希望在不久的将来将这种创新疫苗推向中国市场，这将对老龄化社会的疾病预防和控制具有重要意义。”。
Riding BRI, vaccine giant seeks more cooperation with overseas partnersChinese vaccine company Sinovac Biotech is in talks with potential partners to localize the production of its vaccines in more foreign countries, said its executives.
借助“一带一路”倡议，疫苗巨头寻求与海外合作伙伴开展更多合作。中国疫苗公司科兴生物技术有限公司高管表示，该公司正在与潜在合作伙伴进行谈判，以将其疫苗生产本地化到更多外国。
By localizing production through technology transfer and cooperation, Sinovac aims to achieve win-win results with foreign partners, including improving vaccine affordability and accessibility in host countries and spurring the development of the local vaccine and pharmaceutical sectors, the company said.
该公司表示，通过技术转让和合作实现生产本地化，科兴旨在与外国合作伙伴实现双赢，包括提高疫苗在东道国的可负担性和可及性，并促进当地疫苗和制药行业的发展。
During the COVID-19 pandemic, the company realized the international community had fully recognized the competitiveness of Chinese vaccines.
在新冠肺炎大流行期间，该公司意识到国际社会已经充分认识到中国疫苗的竞争力。
A more important role that Chinese biotech companies like Sinovac could play is cooperating with foreign partners to localize the production of Chinese vaccines rather than exporting the products.
像科兴这样的中国生物技术公司可以发挥的一个更重要的作用是与外国合作伙伴合作，将中国疫苗的生产本地化，而不是出口产品。
The company's vaccine plans involving such technology transfer and localized production cooperation mainly include those for hepatitis A, polio, influenza and COVID-19.
该公司涉及此类技术转让和本地化生产合作的疫苗计划主要包括针对甲型肝炎、脊髓灰质炎、流感和新冠肺炎的疫苗计划。
During the post-pandemic era, many countries are still interested in obtaining COVID-19 vaccine production technology, in case of any future outbreaks, Yang said.
杨说，在后疫情时代，许多国家仍然有兴趣获得新冠肺炎疫苗生产技术，以防未来爆发疫情。
"In the past, we only provided vaccines.
“过去，我们只提供疫苗。
But when a pandemic comes, providing just vaccines is not enough," Yang said.
但当疫情来临时，仅仅提供疫苗是不够的，”杨说。
The pandemic taught us that vaccine production capacity is a matter of public safety and national security.
新冠疫情告诉我们，疫苗生产能力事关公共安全和国家安全。
We are welcomed by leaders of foreign countries to transfer technology and cooperate on localizing vaccine production," she added.
我们欢迎外国领导人在疫苗生产本地化方面进行技术转让和合作，”她补充道。
Under the framework of the BRI, the company can make foreign investments, establish joint ventures, engage in research and production partnerships, and jointly develop high-quality vaccines and other biopharmaceutical products with partners, he said.
他说，在“一带一路”倡议的框架下，该公司可以进行外国投资，建立合资企业，建立研究和生产伙伴关系，并与合作伙伴共同开发高质量的疫苗和其他生物制药产品。
China is among the few developing countries with full industrial and supply chains for the production of a myriad of vaccines via multiple technological routes, Yang said.
杨说，中国是少数几个拥有完整产业链和供应链的发展中国家之一，可以通过多种技术途径生产大量疫苗。
Localized production of Chinese vaccines not only improves the affordability and accessibility of vaccines for partner countries but also helps to cultivate talent and enhance medicine regulation, including clinical results review and product registration, she added.
她补充道，中国疫苗的本地化生产不仅提高了伙伴国家疫苗的可负担性和可及性，而且有助于培养人才和加强药品监管，包括临床结果审查和产品注册。
So far, Sinovac has entered into 17 technology licensing agreements for vaccine production in 12 countries, including seven countries participating in the BRI.
到目前为止，科兴已在12个国家签订了17项疫苗生产技术许可协议，其中包括7个参与“一带一路”倡议的国家。
Its flagship vaccine, the inactivated vaccine against COVID-19, has realized localized production in five countries involved in the initiative — Indonesia, Turkiye, Egypt, Malaysia and Algeria.
其旗舰疫苗新冠肺炎灭活疫苗已在印度尼西亚、土耳其、埃及、马来西亚和阿尔及利亚五个参与该倡议的国家实现了本地化生产。
In Turkiye, Sinovac and its local partner have built a formulation and packaging facility that will further enhance the country's vaccine production capacity.
在土耳其，科兴公司及其当地合作伙伴建立了一个配方和包装设施，这将进一步提高该国的疫苗生产能力。
Its advanced automated storage center in Egypt, which is currently the largest vaccine storage facility in Africa, will significantly boost Egypt's cold chain vaccine storage and distribution capabilities, consequently improving the vaccine supply chain across the continent.
其位于埃及的先进自动化储存中心目前是非洲最大的疫苗储存设施，将大大提高埃及的冷链疫苗储存和分销能力，从而改善整个非洲大陆的疫苗供应链。
According to the China Association for Vaccines, Chinese vaccine manufacturers have made substantial progress in strengthening their position in global vaccine value chains through transferring technologies, building overseas production sites, expanding cooperation on research and development and licensing out.
中国疫苗协会表示，中国疫苗制造商通过转让技术、建设海外生产基地、扩大研发合作和许可证发放，在加强其在全球疫苗价值链中的地位方面取得了实质性进展。
Yet, in seeking a greater global presence, Chinese vaccine makers must improve corporate governance, align with international standards, cultivate talent and build efficient cooperation networks with local partners, the report said.
然而，报告称，在寻求更大的全球影响力时，中国疫苗制造商必须改善公司治理，与国际标准保持一致，培养人才，并与当地合作伙伴建立高效的合作网络。
With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to introduce over 50 innovative drugs, vaccines, new indications and companion diagnostics to China in the next five years.
凭借对中国市场的长期承诺，总部位于美国的全球制药公司默沙东计划在未来五年内向中国引进50多种创新药物、疫苗、新适应症和配套诊断。
The company, which specializes in innovative medicines and vaccines, said that the commercialization of the medicine in China marks Everest's transformation into a commercial-stage innovative biopharmaceutical company.
这家专门从事创新药物和疫苗的公司表示，该药物在中国的商业化标志着珠穆朗玛峰向商业阶段的创新生物制药公司转型。
US mRNA vaccine developer Moderna signed a strategic cooperation contract with Shanghai authorities on Wednesday.
周三，美国信使核糖核酸疫苗开发商莫德纳与上海当局签署了一份战略合作合同。
One of the world's leading mRNA vaccine developers, Moderna focuses on cancer immunotherapy, mRNA-based medicine R&D and virus prevention technologies.
作为世界领先的mRNA疫苗开发商之一，Moderna专注于癌症免疫疗法、基于mRNA的药物研发和病毒预防技术。
Sanofi's vaccine manufacturing base in Shenzhen has realized localized production of flu vaccines and the Hangzhou manufacturing site is already an important facility in manufacturing solid preparations.
赛诺菲在深圳的疫苗生产基地已经实现了流感疫苗的本地化生产，杭州的生产基地已经是生产固体制剂的重要设施。
"We expect to introduce more than 25 innovative products into China between 2020 and 2025, covering immunity and inflammation, rare diseases and rare blood diseases, oncology, vaccines, cardiovascular and diabetes," Shi added.
施补充道：“我们预计在2020年至2025年期间将向中国引进超过25种创新产品，涵盖免疫和炎症、罕见病和罕见血液病、肿瘤学、疫苗、心血管和糖尿病。”。
Two-dose bivalent vaccine for the human papilloma virus (HPV) becomes available in China, in an effort to better help women fight cervical cancer, according to British drugmaker GlaxoSmithKline.
英国制药商葛兰素史克（GlaxoSmithKline）表示，为了更好地帮助女性对抗宫颈癌症，中国将提供两剂二价人类乳头状瘤病毒疫苗。
Feng Bixia, the company's vice-president, said that Cervarix, the first HPV vaccine licensed for use in China, has extended its coverage to more than 280 Chinses cities since 2016, playing a vital role in protecting women from the threat of cervical cancer.
该公司副总裁冯碧霞表示，Cervarix是中国首款获准使用的HPV疫苗，自2016年以来，其覆盖范围已扩大到中国280多个城市，在保护女性免受癌症威胁方面发挥着至关重要的作用。
Going forward, the company will work with various stakeholders to accelerate vaccine innovation, enhance vaccine accessibility, lighten people's financial burden and put healthcare resources to more effective uses, she added.
她补充道，未来，该公司将与各利益相关者合作，加快疫苗创新，提高疫苗的可及性，减轻人们的经济负担，并使医疗资源得到更有效的利用。
France-based pharmaceutical and healthcare company Sanofi aims to more than double its sales of vaccines globally by 2030 compared with 2018, said a senior executive of the company.
总部位于法国的制药和医疗保健公司赛诺菲的一位高管表示，该公司的目标是到2030年，其全球疫苗销售额比2018年翻一番以上。
The company is committed to accelerating the launch of more innovative technologies and preventive solutions in the market to support the ambitions, said Thomas Triomphe, executive vice-president and head of vaccines at Sanofi.
赛诺菲执行副总裁兼疫苗主管Thomas Triomphe表示，该公司致力于加快在市场上推出更多创新技术和预防性解决方案，以支持这一雄心。
"China has become one of the major growth drivers for our global vaccine business.
“中国已成为我们全球疫苗业务的主要增长动力之一。
The quadrivalent flu vaccine Vaxigrip was approved in China in February for pediatric indications.
四价流感疫苗Vaxigrip于2月在中国获批用于儿科适应症。
"I believe that the vaccine industry in China and worldwide is likely to ride a new wave of strong growth in the post-COVID-19 pandemic era," said Triomphe.
Triomphe表示：“我相信，在新冠肺炎疫情后的时代，中国和世界各地的疫苗行业可能会迎来新一波强劲增长。”。
"By 2025, we aim to have 10 new vaccines in clinical trials, including six with mRNA technologies," said Triomphe.
Triomphe说：“到2025年，我们的目标是有10种新疫苗进行临床试验，其中6种采用信使核糖核酸技术。”。
With the platform, Sanofi also aims to deliver next-generation mRNA flu vaccines.
借助该平台，赛诺菲还致力于提供下一代信使核糖核酸流感疫苗。
China's vaccine market has great growth potential, he added, as the Chinese government has been continually raising public vaccination levels on the way to fulfill its Healthy China 2030 initiative.
他补充道，中国疫苗市场具有巨大的增长潜力，因为中国政府在实现其“健康中国2030”倡议的过程中不断提高公众疫苗接种水平。
"China's achievement in developing a robust public health system has been remarkable over the past years and vaccine use in the country has expanded largely.
“过去几年，中国在发展强大的公共卫生系统方面取得了显著成就，疫苗在中国的使用也大幅扩大。
"With local vaccine companies improving their technology, I believe the excellence in production, logistics and supply can further benefit the country in realizing high-quality development," Triomphe stated.
Triomphe表示：“随着当地疫苗公司提高技术，我相信在生产、物流和供应方面的卓越表现可以进一步有利于国家实现高质量发展。”。
Shenzhen is home to Sanofi's flu vaccine production plant built in 2007, the first and only foreign-owned vaccine production site in China.
深圳是赛诺菲流感疫苗生产厂的所在地，该厂建于2007年，是中国第一家也是唯一一家外资疫苗生产厂。
In 2021, the company inaugurated its Greater Bay Area International Vaccine Innovation Center in the city.
2021年，该公司在该市成立了大湾区国际疫苗创新中心。
When influenza vaccination rates among school-age children in Shenzhen participating in the study increased from 42 percent to 76 percent, the vaccine could be an effective measure to slash the financial burden of hospitalization by 107 million yuan ($15.53 million).
当参与这项研究的深圳学龄儿童的流感疫苗接种率从42%提高到76%时，该疫苗可能是一项有效措施，可以减少1.07亿元（1553万美元）的住院经济负担。
The two sides agreed to accelerate the market access to innovative vaccines and promote innovative development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area.
双方同意加快创新疫苗市场准入，推动广东-香港-马考大湾区生物医药产业创新发展。
Thomas Triomphe, executive vice president and head of vaccines at Sanofi, said the company is currently committed to promoting the landing of several innovative product pipelines in China.
赛诺菲执行副总裁兼疫苗主管Thomas Triomphe表示，该公司目前正致力于推动几条创新产品管道在中国落地。
"Sanofi's steady growth in China, especially in vaccines, owes much to the open international business environment created by the Shenzhen municipal government and Pingshan district," said Triomphe.
Triomphe表示：“赛诺菲在中国的稳步增长，尤其是在疫苗方面，很大程度上归功于深圳市政府和平山区创造的开放的国际商业环境。”。
French pharmaceutical company Sanofi on Tuesday signed a partnership agreement with the Pingshan district government in Shenzhen to accelerate the introduction of innovative vaccines to the Chinese market.
法国制药公司赛诺菲周二与深圳市平山区政府签署了一项合作协议，以加快将创新疫苗引入中国市场。
According to the agreement, the two sides will also leverage the Greater Bay Area International Vaccine Innovation Center, which was jointly established by the company and the Shenzhen government, as a platform to promote the innovative development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).
根据协议，双方还将利用公司与深圳市政府共同成立的大湾区国际疫苗创新中心，作为推动广东-香港-马考大湾区生物制药产业创新发展的平台。
Thomas Triomphe, executive vice-president, head of vaccines, Sanofi, said the company's growth in China, especially in vaccines, is largely due to the open, international business environment in Shenzhen city and Pingshan district.
赛诺菲执行副总裁兼疫苗主管Thomas Triomphe表示，该公司在中国的增长，尤其是在疫苗方面，很大程度上归功于深圳市和平山区开放的国际商业环境。
Sanofi and the Shenzhen government had previously in 2019 signed a memorandum of understanding regarding a strategic cooperation in vaccine innovation.
赛诺菲和深圳政府此前于2019年签署了一份关于疫苗创新战略合作的谅解备忘录。
In 2021, the two parties established the GBA International Vaccine Innovation Center in Pingshan district.
2021年，双方在平山区成立了GBA国际疫苗创新中心。
Everest Medicines, a Hong Kong-listed Chinese biopharmaceutical company, announced the official opening of its messenger RNA vaccine industrialization base in Jiashan, Zhejiang province, on Tuesday.
周二，在香港上市的中国生物制药公司Everest Medicines宣布，其位于浙江嘉善的信使核糖核酸疫苗产业化基地正式启用。
With a focus on innovative medicines and the discovery, development, and commercialization of mRNA vaccines, the company said the annual production capacity from the base is expected to reach 700 million doses.
该公司专注于创新药物以及信使核糖核酸疫苗的发现、开发和商业化，表示该基地的年产能预计将达到7亿剂。
Everest said the base launched trial production in December and has proven capable of large-scale production of mRNA vaccines.
Everest表示，该基地于12月开始试生产，并已证明有能力大规模生产信使核糖核酸疫苗。
Due to the COVID-19 pandemic and a surge in demand for related vaccines, mRNA technology has received extensive attention and accelerated research.
由于新冠肺炎大流行和对相关疫苗的需求激增，mRNA技术受到了广泛关注并加速了研究。
"We'll continue to accelerate clinical trials of related products and strive to realize their commercialization as soon as possible to meet the urgent demand for advanced mRNA vaccines in Greater China, Asia and the world," Everest CEO Luo Yongqing said.
珠峰首席执行官罗永清表示：“我们将继续加快相关产品的临床试验，并努力尽快实现其商业化，以满足大中华区、亚洲和世界对先进信使核糖核酸疫苗的迫切需求。”。
The company has announced its formulation of a candidate COVID-19 vaccine, with clinical trials scheduled to kick off in China this year.
该公司宣布了其候选新冠肺炎疫苗的配方，临床试验计划于今年在中国启动。
In addition, the company said it is exploring the potential of mRNA technology and will develop new preventive and therapeutic vaccines for infectious diseases and tumors.
此外，该公司表示，正在探索信使核糖核酸技术的潜力，并将开发新的传染病和肿瘤预防和治疗疫苗。
The drop in January-November profits was mainly driven by declining profits in the steel and oil processing sectors and two key COVID-19 vaccine enterprises, NBS senior statistician Zhu Hong said in a statement accompanying the data.
国家统计局高级统计师朱红在数据附带的一份声明中表示，1月至11月利润下降的主要原因是钢铁和石油加工行业以及两家新冠肺炎疫苗关键企业的利润下降。
"We are partnering with innovative Chinese companies, like Wuxi Biologics, to further expand our partnership in COVID-19 vaccines, as well neutralizing anti-bodies," he said.
他说：“我们正在与无锡生物等创新型中国公司合作，进一步扩大我们在新冠肺炎疫苗以及中和抗体方面的合作伙伴关系。”。
The China International Import Expo has provided Sanofi Vaccines a deeper understanding about the vitality and potential of the Chinese market, making the company more confident, more determined, and more ambitious to thrive in China, according to a top executive of the company.
赛诺菲公司的一位高管表示，中国国际进口博览会让赛诺菲疫苗对中国市场的活力和潜力有了更深入的了解，使该公司更有信心、更有决心、更有雄心在中国蓬勃发展。
Zhang Heping, head of Sanofi Vaccines Greater China, made the remarks as the fifth CIIE concluded on Thursday.
赛诺菲疫苗大中华区负责人张和平在第五届进博会周四闭幕时发表了上述讲话。
"This is the fifth time Sanofi Vaccines has attended the CIIE," Zhang said, adding the company has showcased its achievements in efficient detection, innovative approaches, smart vaccination and talent development at this year's CIIE.
“这是赛诺菲疫苗第五次参加进博会，”张说，并补充说，该公司在今年的进博会上展示了其在高效检测、创新方法、智能疫苗接种和人才培养方面的成就。
"Benefiting from the great influence of the CIIE and the 'China speed' generated by its strong spillover effect, Sanofi Vaccines' vision, partnerships and innovations that have developed from attending the CIIE in the past four years are turning into tangible results, and at an accelerated pace, to help safeguarding the health of more people in China," he said.
他说：“得益于进博会的巨大影响力及其强大的溢出效应所产生的‘中国速度’，赛诺菲疫苗在过去四年中从参加进博会发展起来的愿景、合作伙伴关系和创新正在加速转化为实实在在的成果，以帮助保障中国更多人的健康。”。
Sinovac's COVID-19 vaccines are widely popular in Türkiye's national vaccination campaign.
科兴新冠肺炎疫苗在土耳其全国疫苗接种运动中广受欢迎。
The vials produced by the plant have been used to store COVID-19 vaccines.
该工厂生产的小瓶已用于储存新冠肺炎疫苗。
The company also expects to finish clinical trials on Omicron-specific vaccines by September, and will closely track any mutations of the new coronavirus variant to develop new vaccines, he said.
他说，该公司还预计将在9月前完成奥密克戎特异性疫苗的临床试验，并将密切跟踪新冠病毒变种的任何突变，以开发新疫苗。
Sinopharm is the only enterprise in the world to have independently developed four COVID-19 vaccines via three technical platforms－two inactivated vaccines, one genetic recombinant vaccine and one mRNA vaccine.
国药集团是世界上唯一一家通过三个技术平台自主研发4种新冠肺炎疫苗的企业——两种灭活疫苗、一种基因重组疫苗和一种mRNA疫苗。
To date, COVID-19 vaccines made by Sinopharm have been approved for use or market entry by more than 119 countries, regions and international organizations.
迄今为止，国药集团生产的新冠肺炎疫苗已被119多个国家、地区和国际组织批准使用或进入市场。
By the end of 2021, the company had supplied the world with 3.5 billion doses of COVID-19 vaccines through production both at home and abroad.
截至2021年底，该公司已通过国内外生产向全球供应了35亿剂新冠肺炎疫苗。
The company also expects to finish clinical trials on Omicron-specific vaccines by September and will track closely the mutation of new variants to develop new vaccines, he said.
他说，该公司还预计在9月前完成奥密克戎特异性疫苗的临床试验，并将密切跟踪新变种的突变，以开发新疫苗。
Sinopharm is the only enterprise in the world that has independently developed four COVID-19 vaccines via three technical platforms -- two inactivated vaccines, one genetic recombinant vaccine and one mRNA vaccine.
国药集团是全球唯一一家通过两种灭活疫苗、一种基因重组疫苗和一种mRNA疫苗三大技术平台自主研发四种新冠肺炎疫苗的企业。
By the end of 2021, the company had supplied 3.5 billion doses of COVID-19 vaccines through production at both home and abroad.
截至2021年底，该公司已通过国内外生产供应了35亿剂新冠肺炎疫苗。
The therapy can provide lasting protection for a wide range of people with poor immunity and who are not fully protected by COVID-19 vaccines, and for those who are at high risk of virus exposure.
该疗法可以为免疫力差、没有得到新冠肺炎疫苗充分保护的人群以及病毒暴露风险高的人群提供持久保护。
Sinovac Biotech's COVID-19 vaccine called CoronaVac has been approved for children aged six months to three years in Hong Kong from Thursday, the Beijing-based biopharmaceutical product provider said on Wednesday.
总部位于北京的生物制药产品提供商科兴生物周三表示，该公司的新冠肺炎疫苗CoronaVac已于周四在香港获准用于6个月至3岁的儿童。
Three doses of vaccines will be used, with the first two doses given 28 days apart followed by a third dose at least 3 months after the second dose, and there is no restriction on the application for immunosuppressed children.
将使用三剂疫苗，前两剂间隔28天接种，第二剂接种后至少3个月接种第三剂，免疫抑制儿童的应用没有限制。
China's COVID-19 vaccine makers are expected to step up efforts to pursue innovation-driven high-quality development, based on their fast growth in the past few years, according to industry experts and business leaders.
行业专家和商界领袖表示，预计中国新冠肺炎疫苗制造商将在过去几年快速增长的基础上，加大力度，追求创新驱动的高质量发展。
Since the outbreak of the disease, Chinese vaccine developers have moved swiftly to design vaccines against the contagion.
自该疾病爆发以来，中国疫苗开发商迅速采取行动，设计出对抗传染病的疫苗。
So far, the country has approved seven homegrown COVID-19 vaccines for the domestic market.
到目前为止，该国已批准七种国产新冠肺炎疫苗进入国内市场。
The total number of COVID-19 vaccine doses administered on the Chinese mainland was around 3.41 billion as of July 14, data from the National Health Commission showed.
国家卫生健康委员会的数据显示，截至7月14日，中国大陆接种新冠肺炎疫苗的总剂量约为34.1亿剂。
Data from the Ministry of Commerce showed China has provided more than 2.2 billion doses of COVID-19 vaccines to more than 120 countries, regions and international organizations.
商务部的数据显示，中国已向120多个国家、地区和国际组织提供了超过22亿剂新冠肺炎疫苗。
However, analysts said domestic vaccine producers must face the reality of shrinking demand for COVID-19 vaccines, and refocus on product quality improvements while strengthening efforts to better meet disease prevention goals in both global and domestic markets.
然而，分析人士表示，国内疫苗生产商必须面对新冠肺炎疫苗需求萎缩的现实，在加强努力以更好地实现全球和国内市场的疾病预防目标的同时，重新关注产品质量改进。
A report from Southwest Securities said nearly 64 percent of the world's population has already been vaccinated with at least one dose of a COVID vaccine, while around 57 percent have been fully inoculated.
西南证券的一份报告称，全球近64%的人口已经接种了至少一剂新冠疫苗，而约57%的人已经完全接种。
This means demand for COVID-19 vaccines for basic inoculation programs will be around 3.3 billion doses globally, while the figure for booster vaccines is expected to be 6.1 billion doses worldwide, the report estimated.
报告估计，这意味着全球基本接种计划对新冠肺炎疫苗的需求将约为33亿剂，而全球加强疫苗的需求预计为61亿剂。
So far, three Chinese COVID-19 vaccines, manufactured by China National Biotec Group, Sinovac Biotech Ltd and CanSino Biologics Inc, have won emergency use approval from the World Health Organization.
到目前为止，由中国生物技术集团、科兴生物技术有限公司和康希诺生物制品公司生产的三种中国新冠肺炎疫苗已获得世界卫生组织的紧急使用批准。
Chen Jia, a researcher at the International Monetary Institute of the Renmin University of China, said:"Chinese vaccine companies have become more aware of the importance of independent innovation.
中国人民大学国际货币研究所研究员陈佳说：“中国疫苗公司越来越意识到自主创新的重要性。
"In total, more than 119 countries, regions and international organizations have approved the use of COVID-19 vaccines made by CNBG, which has produced more than 3 billion doses of such vaccines at home and overseas.
“总共有119多个国家、地区和国际组织批准使用CNBG生产的新冠肺炎疫苗，该公司已在国内外生产了超过30亿剂此类疫苗。
Sinovac, which has been granted access licenses by more than 60 countries, international organizations and regions in total for its COVID-19 vaccine CoronaVac, has supplied more than 2.8 billion doses worldwide.
科兴公司新冠肺炎疫苗CoronaVac已获得60多个国家、国际组织和地区的准入许可，该公司已在全球供应超过28亿剂疫苗。
Pearson Liu, senior brand director and spokesman for Sinovac, said the company steps up efforts on the R&D and exports of its COVID-19 vaccines.
科兴公司高级品牌总监兼发言人Pearson Liu表示，该公司加大了新冠肺炎疫苗的研发和出口力度。
The company has strengthened its capability in industrial chain coordination and global cooperation regarding key links for vaccine design and supply, such as animal testing, clinical trials, product registration and production.
该公司加强了在动物试验、临床试验、产品注册和生产等疫苗设计和供应关键环节的产业链协调和全球合作能力。
Sinopharm, parent company of CNBG, currently produces nearly 100 vaccine products and more than 200 bio-products.
中国生物天然气集团的母公司国药集团目前生产近100种疫苗产品和200多种生物产品。
Chen, with RUC, said Chinese vaccine makers' deeper participation in global vaccine industrial chains has created favorable conditions for them to increase their presence in global markets.
中国人民大学的陈表示，中国疫苗制造商对全球疫苗产业链的深入参与为他们增加在全球市场的影响力创造了有利条件。
The improvement of Chinese vaccine enterprises' position in the global vaccine industry was achieved in the past two years through expanding production capacity, establishing cross-region logistics, improving commercialization, and strengthening international cooperation, he said.
他说，中国疫苗企业在全球疫苗行业地位的提高是在过去两年中通过扩大产能、建立跨地区物流、提高商业化水平和加强国际合作实现的。
Chen Qiulin, vice-director of the Research Center for Health Industry Development of the Chinese Academy of Social Sciences, also said exporting COVID-19 vaccines has helped Chinese companies accumulate experience in understanding international best practices more deeply, and increase their presence in global markets.
中国社会科学院健康产业发展研究中心副主任陈秋林也表示，出口新冠肺炎疫苗有助于中国企业积累更深入了解国际最佳实践的经验，并增加其在全球市场的影响力。